New Two-Pronged drug tested to shrink tumors before esophageal cancer surgery
NCT ID NCT07244978
Summary
This study is testing a new drug called Ivonescimab, given with standard chemotherapy, to patients with a type of esophageal cancer before they have surgery. The goal is to see if this combination can shrink the tumor more effectively and reduce the chance of the cancer coming back after surgery. Researchers will enroll about 49 patients to check the safety of this approach and how well it works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, 310000, China
Conditions
Explore the condition pages connected to this study.